Antibody-targeted RNase fusion proteins (ImmunoRNases) for cancer therapy

被引：17

作者：

Krauss, Juergen ^{[1
]}

Arndt, Michaela A. E. ^{[1
]}

Duebel, Stefan ^{[2
]}

Rybak, Susanna M. ^{[3
]}

机构：

[1] Univ Heidelberg, Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany

[2] Tech Univ Carolo Wilhelmina Braunschweig, Dept Biotechnol, D-38106 Braunschweig, Germany

[3] Bionanomics LLC, Green Cove Springs, FL 32043 USA

来源：

CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2008年 / 9卷 / 03期

关键词：

RNase; Onconase (R); immunoRNase; antibody-RNase fusion protein; immunotherapeutics;

D O I：

10.2174/138920108784567317

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase (R)), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with un-resectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anticancer therapeutics.

引用

页码：231 / 234

页数：4

共 41 条

[11] Ribonuclease inhibits Kaposi's sarcoma [J].

Griffiths, SJ ;

Adams, DJ ;

Talbot, SJ .

NATURE, 1997, 390 (6660) :568-568

[12] Engineered antibody fragments and the rise of single domains [J].

Holliger, P ;

Hudson, PJ .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1126-1136

[13]

HOOGENBOOM HR, 1990, J IMMUNOL, V144, P3211

[14] Engineered antibodies [J].

Hudson, Peter J. ;

Souriau, Christelle .

NATURE MEDICINE, 2003, 9 (01) :129-134

[15]

Huhn M, 2001, CANCER RES, V61, P8737

[16] Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics [J].

Hursey, M ;

Newton, DL ;

Hansen, HJ ;

Ruby, D ;

Goldenberg, DM ;

Rybak, SM .

LEUKEMIA & LYMPHOMA, 2002, 43 (05) :953-959

[17] Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines - A trial for less immunogenic chimeric toxin [J].

Jinno, H ;

Ueda, M ;

Ozawa, S ;

Kikuchi, K ;

Ikeda, T ;

Enomoto, K ;

Kitajima, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (04) :303-308

[18] Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein [J].

Krauss, J ;

Arndt, MAE ;

Vu, BK ;

Newton, DL ;

Seeber, S ;

Rybak, SM .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 331 (02) :595-602

[19] Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme [J].

Krauss, J ;

Arndt, MAE ;

Vu, BK ;

Newton, DL ;

Rybak, SM .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) :602-609

[20] Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme [J].

Krauss, J ;

Arndt, MAE ;

Zhu, Z ;

Newton, DL ;

Vu, BK ;

Choudhry, V ;

Darbha, R ;

Ji, X ;

Courtenay-Luck, NS ;

Deonarain, MP ;

Richards, J ;

Rybak, SM .

BRITISH JOURNAL OF CANCER, 2004, 90 (09) :1863-1870

← 1 2 3 4 5 →